HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat (class I and II HDAC inhibitor) was the first HDAC inhibitor to gain FDA approval in 2006 for the treatment of cutaneous T-cell lymphoma (CTCL).